Evidence map›Paper›PMID 24043270›Full record

ArticleJAMA internal medicine2013

National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011.

Raymund Dantes, Yi Mu, Ruth Belflower, Deborah Aragon, Ghinwa Dumyati, Lee H Harrison, Fernanda C Lessa, Ruth Lynfield, Joelle Nadle, Susan Petit and 5 more

Abstract read
In one paragraph

Article in JAMA internal medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 272 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
272citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

272 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. A Six-Year Retrospective Surveillance of OutpatientInfectious diseases & clinical microbiology · 2026
    Article
  8. Factors associated with methicillin resistance in Staphylococcus aureus: a case-case-control analysis of AMR surveillance data.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  9. Whole-genome sequencing ofMicrobiology spectrum · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Methicillin-resistantCurrent pharmaceutical biotechnology · 2025
    Review
  17. Review
  18. Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000-2021.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  19. Article
  20. Article

212 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Raymund DantesEpidemic Intelligence Service, Scientific Education and Professional Development Program Office, Centers for Disease Control and Prevention, Atlanta, Georgia2Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Yi Mu
Ruth Belflower
Deborah Aragon
Ghinwa Dumyati
Lee H Harrison
Fernanda C Lessa
Ruth Lynfield
Joelle Nadle
Susan Petit
Susan M Ray
William Schaffner
John Townes
Scott Fridkin
Emerging Infections Program–Active Bacterial Core Surveillance MRSA Surveillance Investigators

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

importanceEstimating the US burden of methicillin-resistant Staphylococcus aureus (MRSA) infections is important for planning and tracking success of prevention strategies.

objectiveTo describe updated national estimates and characteristics of health care- and community-associated invasive methicillin-resistant Staphylococcus aureus (MRSA) infections in 2011. DESIGN, SETTING, AND

participantsActive laboratory-based case finding identified MRSA cultures in 9 US metropolitan areas from 2005 through 2011. Invasive infections (MRSA cultured from normally sterile body sites) were classified as health care-associated community-onset (HACO) infections (cultured ≤ 3 days after admission and/or prior year dialysis, hospitalization, surgery, long-term care residence, or central vascular catheter presence ≤ 2 days before culture); hospital-onset infections (cultured >3 days after admission); or community-associated infections if no other criteria were met. National estimates were adjusted using US census and US Renal Data System data. MAIN OUTCOMES AND MEASURES: National estimates of invasive HACO, hospital-onset, and community-associated MRSA infections using US census and US Renal Data System data as the denominator.

resultsAn estimated 80,461 (95% CI, 69,515-93,914) invasive MRSA infections occurred nationally in 2011. Of these, 48,353 (95% CI, 40,195-58,642) were HACO infections; 14,156 (95% CI, 10,096-20,440) were hospital-onset infections; and 16,560 (95% CI, 12,806-21,811) were community-associated infections. Since 2005, adjusted national estimated incidence rates decreased among HACO infections by 27.7% and hospital-onset infections decreased by 54.2%; community-associated infections decreased by only 5.0%. Among recently hospitalized community-onset (nondialysis) infections, 64% occurred 3 months or less after discharge, and 32% of these were admitted from long-term care facilities. CONCLUSIONS AND RELEVANCE: An estimated 30,800 fewer invasive MRSA infections occurred in the United States in 2011 compared with 2005; in 2011 fewer infections occurred among patients during hospitalization than among persons in the community without recent health care exposures. Effective strategies for preventing infections outside acute care settings will have the greatest impact on further reducing invasive MRSA infections nationally.

Indexed as

Cost of IllnessMethicillin-Resistant Staphylococcus aureusAdolescentAdultAgedChildChild, PreschoolCommunity-Acquired InfectionsCross InfectionFemaleHospitalizationHumansInfantLong-Term CareMaleMiddle Aged

Identifiers

PMID24043270
PMCPMC10887428

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.